PPD Launches PPD DirectConnect(TM), Unique Secured Client Web Portal For Clinical Trial Project Management

Client-Proven Technology Is First Component of Comprehensive

E-Clinical Trials Initiative



Apr 16, 2001, 01:00 ET from PPD, Inc.

    WILMINGTON, N.C., April 16 /PRNewswire/ -- PPD, Inc. (Nasdaq:   PPDI) today
 launched PPD DirectConnect(TM), a customizable suite of secure, Web-based
 project management tools, giving clients online access to the latest data from
 their clinical trials.
     Through the PPD DirectConnect platform, PPD can now offer clients a
 secured Web site tailored to their specifications that lets them closely
 monitor trial progress through online, print-ready project status reports.  In
 addition, clients can review draft deliverables, reports and submission
 documents online, thus expediting the overall study process.  PPD
 DirectConnect users also can download project data files at their convenience
 using a secure file transfer site.
     During its development with clients, the PPD DirectConnect technology was
 used by more than 350 client project team members across 20 PPD managed
 clinical trials from a cross-section of ethical and generic pharmaceutical
 companies as well as biotechnology firms.
     "Client-tested and client-honed, PPD DirectConnect is now available to
 help us work more closely with all of our development services clients," said
 Fred Eshelman, chief executive officer with PPD.  "As the first component in
 our e-clinical trials initiative, PPD DirectConnect supports our overall goal
 of strengthening client partnerships while improving the speed and quality of
 clinical trials."
     PPD DirectConnect offers immediate access to data from specific studies,
 including current trial results, medical reports, approved trial protocols and
 case report forms.  In addition, clients can view standard information across
 studies such as standard operating procedures and requests for proposals, bids
 and contracts.  To facilitate communications, each client Web portal also
 includes a profile of project team members with contact information and direct
 e-mail links.
     According to Liz Rolison, PPD's vice president of Informatics, feedback
 from clients who used the PPD DirectConnect platform during its initial
 development convinced the company that all PPD customers could benefit from
 the technology.
     "Individually and as a group, clients have praised the product for its
 ease of use, flexibility and power to streamline the study process," said
 Rolison.
     Rolison emphasized that PPD DirectConnect offers PPD clients a wide array
 of features and options that are customized to suit individual parameters.
 "On top of the standard offering, clients select the specific functions they
 want and we build the site according to their specifications," she said.
 Rolison noted that PPD is continuing to expand and refine the PPD
 DirectConnect suite based on client input.
     PPD DirectConnect requires no additional software or technology upgrades
 because it is designed to work with all major commercially available Web
 browsers, including those offered by Microsoft and Netscape.  Clients access
 their PPD DirectConnect Web portal on a secure extranet site residing on a
 dedicated server that sits inside the PPD firewall but outside of PPD's
 internal network.  PPD DirectConnect offers secured access using SSL (Secured
 Socket Layer) protocol for encryption and security authorization.
 
     About PPD
     PPD, Inc. is a leading global provider of discovery and development
 services and products for the pharmaceutical and biotechnology industries.
 With a corporate mission to provide services that maximize the return on
 clients' R&D investments, PPD provides innovative technologies, therapeutic
 expertise and comprehensive services for drug discovery and preclinical
 programs, Phase I-IV clinical development and post-market support.  The
 company has more than 3,800 professionals in 47 offices in 19 countries around
 the world.  For more information on PPD, visit the Web site at
 http://www.ppdi.com.
 
     Except for historical information, all of the statements, expectations and
 assumptions, including expectations and assumptions about the value of this
 technology offering to PPD, contained in the foregoing are forward-looking
 statements that involve a number of risks and uncertainties.  Although PPD has
 used its best efforts to be accurate in making those forward-looking
 statements, it is possible that the assumptions made by management may not
 materialize.  In addition, other important factors which could cause results
 to differ materially include the following:  economic conditions in the
 pharmaceutical and biotechnology industries; outsourcing trends in the
 pharmaceutical and biotechnology industries; dependence on collaborative
 relationships; rapid technological advances that make our products and
 services less competitive; loss of large contracts; competition within the
 outsourcing industry; continued success in sales growth; the ability to
 attract and retain key personnel; and the other risk factors set forth from
 time to time in the Company's SEC filings, copies of which are available upon
 request from PPD's investor relations department.
 
     Contact: Media, Nancy Zeleniak, 919 462 4088, or
                     nancy.zeleniak@rtp.ppdi.com.
              Finance, Jimmy Sloan, 910 772 7168, or
                     jimmy.sloan@wilm.ppdi.com
 
 

SOURCE PPD, Inc.
    WILMINGTON, N.C., April 16 /PRNewswire/ -- PPD, Inc. (Nasdaq:   PPDI) today
 launched PPD DirectConnect(TM), a customizable suite of secure, Web-based
 project management tools, giving clients online access to the latest data from
 their clinical trials.
     Through the PPD DirectConnect platform, PPD can now offer clients a
 secured Web site tailored to their specifications that lets them closely
 monitor trial progress through online, print-ready project status reports.  In
 addition, clients can review draft deliverables, reports and submission
 documents online, thus expediting the overall study process.  PPD
 DirectConnect users also can download project data files at their convenience
 using a secure file transfer site.
     During its development with clients, the PPD DirectConnect technology was
 used by more than 350 client project team members across 20 PPD managed
 clinical trials from a cross-section of ethical and generic pharmaceutical
 companies as well as biotechnology firms.
     "Client-tested and client-honed, PPD DirectConnect is now available to
 help us work more closely with all of our development services clients," said
 Fred Eshelman, chief executive officer with PPD.  "As the first component in
 our e-clinical trials initiative, PPD DirectConnect supports our overall goal
 of strengthening client partnerships while improving the speed and quality of
 clinical trials."
     PPD DirectConnect offers immediate access to data from specific studies,
 including current trial results, medical reports, approved trial protocols and
 case report forms.  In addition, clients can view standard information across
 studies such as standard operating procedures and requests for proposals, bids
 and contracts.  To facilitate communications, each client Web portal also
 includes a profile of project team members with contact information and direct
 e-mail links.
     According to Liz Rolison, PPD's vice president of Informatics, feedback
 from clients who used the PPD DirectConnect platform during its initial
 development convinced the company that all PPD customers could benefit from
 the technology.
     "Individually and as a group, clients have praised the product for its
 ease of use, flexibility and power to streamline the study process," said
 Rolison.
     Rolison emphasized that PPD DirectConnect offers PPD clients a wide array
 of features and options that are customized to suit individual parameters.
 "On top of the standard offering, clients select the specific functions they
 want and we build the site according to their specifications," she said.
 Rolison noted that PPD is continuing to expand and refine the PPD
 DirectConnect suite based on client input.
     PPD DirectConnect requires no additional software or technology upgrades
 because it is designed to work with all major commercially available Web
 browsers, including those offered by Microsoft and Netscape.  Clients access
 their PPD DirectConnect Web portal on a secure extranet site residing on a
 dedicated server that sits inside the PPD firewall but outside of PPD's
 internal network.  PPD DirectConnect offers secured access using SSL (Secured
 Socket Layer) protocol for encryption and security authorization.
 
     About PPD
     PPD, Inc. is a leading global provider of discovery and development
 services and products for the pharmaceutical and biotechnology industries.
 With a corporate mission to provide services that maximize the return on
 clients' R&D investments, PPD provides innovative technologies, therapeutic
 expertise and comprehensive services for drug discovery and preclinical
 programs, Phase I-IV clinical development and post-market support.  The
 company has more than 3,800 professionals in 47 offices in 19 countries around
 the world.  For more information on PPD, visit the Web site at
 http://www.ppdi.com.
 
     Except for historical information, all of the statements, expectations and
 assumptions, including expectations and assumptions about the value of this
 technology offering to PPD, contained in the foregoing are forward-looking
 statements that involve a number of risks and uncertainties.  Although PPD has
 used its best efforts to be accurate in making those forward-looking
 statements, it is possible that the assumptions made by management may not
 materialize.  In addition, other important factors which could cause results
 to differ materially include the following:  economic conditions in the
 pharmaceutical and biotechnology industries; outsourcing trends in the
 pharmaceutical and biotechnology industries; dependence on collaborative
 relationships; rapid technological advances that make our products and
 services less competitive; loss of large contracts; competition within the
 outsourcing industry; continued success in sales growth; the ability to
 attract and retain key personnel; and the other risk factors set forth from
 time to time in the Company's SEC filings, copies of which are available upon
 request from PPD's investor relations department.
 
     Contact: Media, Nancy Zeleniak, 919 462 4088, or
                     nancy.zeleniak@rtp.ppdi.com.
              Finance, Jimmy Sloan, 910 772 7168, or
                     jimmy.sloan@wilm.ppdi.com
 
 SOURCE  PPD, Inc.